ES2123514T3 - Conjugados con receptor, destinados a dirigir farmacos y otros agentes. - Google Patents

Conjugados con receptor, destinados a dirigir farmacos y otros agentes.

Info

Publication number
ES2123514T3
ES2123514T3 ES91915386T ES91915386T ES2123514T3 ES 2123514 T3 ES2123514 T3 ES 2123514T3 ES 91915386 T ES91915386 T ES 91915386T ES 91915386 T ES91915386 T ES 91915386T ES 2123514 T3 ES2123514 T3 ES 2123514T3
Authority
ES
Spain
Prior art keywords
agents
pharmaces
conjugated
receiver
direct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91915386T
Other languages
English (en)
Inventor
Howard C Krivan
Arne Lennart Blomberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emergent Product Development Gaithersburg Inc
Original Assignee
Antex Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antex Biologics Inc filed Critical Antex Biologics Inc
Application granted granted Critical
Publication of ES2123514T3 publication Critical patent/ES2123514T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UNA VARIEDAD DE CONJUGADOS, COMPRENDEN AL MENOS UN AGENTE ACOPLADO A AL MENOS UN RECEPTOR QUE UN MICROORGANISMO, E INCLUYEN ANTIEFECTIVOS, TALES COMO ANTIBIOTICOS Y DROGAS SINTETICAS. EL USO DE LOS CONJUGADOS INCLUYE INHIBIDORES IN VITRO Y AGENTES TERAPEUTICOS, EJM. PARA EL TRATAMIENTO DE INFECCIONES DEBIDAS A MICROORGANISMOS PATOGENICOS
ES91915386T 1991-07-31 1991-07-31 Conjugados con receptor, destinados a dirigir farmacos y otros agentes. Expired - Lifetime ES2123514T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1991/005422 WO1993002709A1 (en) 1991-07-31 1991-07-31 Receptor conjugates for targeting drugs and other agents
CA002114629A CA2114629C (en) 1991-07-31 1991-07-31 Receptor conjugates for targeting antibiotics to bacteria

Publications (1)

Publication Number Publication Date
ES2123514T3 true ES2123514T3 (es) 1999-01-16

Family

ID=25676975

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91915386T Expired - Lifetime ES2123514T3 (es) 1991-07-31 1991-07-31 Conjugados con receptor, destinados a dirigir farmacos y otros agentes.

Country Status (8)

Country Link
EP (1) EP0598719B1 (es)
JP (1) JP3369555B2 (es)
AT (1) ATE171072T1 (es)
CA (1) CA2114629C (es)
DE (1) DE69130235T2 (es)
DK (1) DK0598719T3 (es)
ES (1) ES2123514T3 (es)
WO (1) WO1993002709A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7097839B1 (en) 1993-10-26 2006-08-29 Thomas Jefferson University ST receptor binding compounds and methods of using the same
JPH08133971A (ja) * 1994-09-16 1996-05-28 Toyama Chem Co Ltd 抗ヘリコバクター剤
CA2253204A1 (en) * 1996-05-03 1997-11-13 Roger S. Cubicciotti Prodrug compositions and drug delivery methods using synthetic receptors
CN120678950A (zh) * 2019-01-08 2025-09-23 乔治亚大学研究基金公司 靶向纳米颗粒以及它们的与真菌感染有关的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1165238A (en) * 1980-03-12 1984-04-10 Demetrios P. Papahadjopoulos Activated liposomes and method
SE8501613D0 (sv) * 1985-04-01 1985-04-01 Bio Carb Ab Foreningar for terapeutisk eller diagnostisk anvendning jemte forfarande for terapeutisk behandling
GB8628398D0 (en) * 1986-11-27 1986-12-31 Central Blood Lab Authority Pharmaceutically-active conjugates
DE3711724A1 (de) * 1987-04-07 1988-10-20 Harro Boerner Medizinische Kom System zum einwirken auf, insbesondere zerstoeren von viren
WO1989001519A1 (en) * 1987-08-20 1989-02-23 Children's Hospital Corporation Human mannose binding protein
US5192551A (en) 1989-05-02 1993-03-09 Johns Hopkins University Neutral glycolipid as an adsorbent for enteric viral pathogens
CA2017739A1 (en) * 1989-07-18 1991-01-18 Engelhard Corporation Cis-diamineplatinum complexes with methanediphosphonate and substituted methanediphosphonate ligands as antitumor agents
AU6521790A (en) * 1989-10-13 1991-05-16 Hans Schreier Lipophilic acylpyrazinamide prodrugs

Also Published As

Publication number Publication date
EP0598719A1 (en) 1994-06-01
CA2114629A1 (en) 1993-02-18
EP0598719B1 (en) 1998-09-16
JP3369555B2 (ja) 2003-01-20
DE69130235D1 (de) 1998-10-22
ATE171072T1 (de) 1998-10-15
CA2114629C (en) 2003-01-14
WO1993002709A1 (en) 1993-02-18
DK0598719T3 (da) 1999-06-14
JPH06511466A (ja) 1994-12-22
DE69130235T2 (de) 1999-02-11

Similar Documents

Publication Publication Date Title
SV1995000045A (es) Benzoxazolil- y benzotiazoliloxazolidinonas, ref. le a 30616-sv
ES2180251T3 (es) Comprimido revestido con polimero, que contiene amoxicilina y clavulanato.
MX9204132A (es) Composiciones farmaceuticas que contienen rifaximin y procedimiento para su preparacion.
BR0107246A (pt) Agentes diazabicìclicos ativos no sistema nervoso central
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
ES2190692A1 (es) Formulacion farmaceutica de amoxicilina y clavulanato de potasio.
SV1995000041A (es) Heteroarik-oxazolidinonas de 6 eslabones con contenido de nitrogeno le a 30522-sv
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
CO4560552A1 (es) Antagonistas de receptores de taquicininas no peptidicos
CL2004000675A1 (es) Uso de una combinacion de androgeno de origen biogenico o sintetico y un estrogeno de origen biogenico o sintetico para preparar un medicamento util en el tratamiento del hipogonadismo y enfermedades hipofisis o glandula pituitaria en hombres, para e
ES2171746T3 (es) Empleo de epinastina para el tratamiento de dolores.
MX9307555A (es) Derivados de paclitaxel y formulaciones farmaceuticas que los contienen.
ES2099211T3 (es) Conjugados citomoduladores de miembros de parejas de union especifica.
ES2132105T3 (es) 2-aminometil-cromanos como principios activos en farmacos para el tratamiento de enfermedades del sistema nervioso central.
AR003176A1 (es) Una composicion farmaceutica para inhibir el crecimiento de cancer
ES2134801T3 (es) Monohidrato de hidrocloruro de tiagabina cristalina, su preparacion y su uso.
CO5050328A1 (es) Sistema solvente para la mejor penetracion de compuestos farmaceuticos
FR2735369B1 (fr) Compositions pharmaceutiques a base de sel de sodium du diclofenac et de thiocolchicoside
IT1263840B (it) Formulazioni orali di ubidecarenone in forma di capsule
ES2103493T3 (es) Uso de parathormona, de sus fragmentos biologicamente activos y de peptidos relacionados para el tratamiento del embarazo.
ES2172171T3 (es) Medicamento, que contiene yohimbina y arginina, para el tratamiento de disfunciones erectiles.
ES2133152T3 (es) Composicion de tiotepa liofilizada estable.
AR023781A1 (es) Formulaciones farmaceuticas
AR021463A1 (es) Antibiotico de piridona con perfil de seguridad mejorado
AR022620A1 (es) Aroil aminoacil pirroles para ser usados en el tratamiento de dolor neuropatico

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 598719

Country of ref document: ES